# Impact of different diagnostic measures on drug class association with dementia progression risk: a longitudinal prospective cohort study

**Daman Kaur[a*], Magda Bucholc[b], David P. Finn[c], Stephen Todd[d], KongFatt Wong-Lin[b], Paula L. McClean[a]**

[a] Northern Ireland Centre for Stratified Medicine, Biomedical Sciences Research Institute, Ulster University, Clinical Translational Research and Innovation Centre (C-TRIC), Altnagelvin Hospital Site, Derry~Londonderry BT47 6SB, Northern Ireland, UK. Ph: +44 (0) 2871675675

[b] Intelligent Systems Research Centre, School of Computing, Engineering and Intelligent Systems, Ulster University, Northland Rd, Derry~Londonderry BT48 7JL, Northern Ireland, UK. Ph: +44 (0) 2871675320

[c] Pharmacology and Therapeutics, School of Medicine, Galway Neuroscience Centre, Human Biology Building, National University of Ireland Galway, University Road, Galway H91 W5P7, Republic of Ireland. Ph: +353-91-495586

[d] Altnagelvin Area Hospital, Western Health and Social Care Trust, Derry~Londonderry BT47 6SB, Northern Ireland, UK. Ph: +44 (0) 2871345171

*Corresponding author: Daman Kaur, kaur-d1@ulster.ac.uk, Northern Ireland Centre for Stratified Medicine, Biomedical Sciences Research Institute, Ulster University, C-TRIC, Altnagelvin Hospital Site, Derry~Londonderry BT47 6SB, Northern Ireland, UK.

Declarations of interest: none

## Abstract

Background: Clinical Dementia Rating Sum of Boxes (CDRSOB) scale is known to be highly indicative of cognitive-functional status, but it is unclear whether it is consistent with clinical diagnosis in evaluating drug class associations with risk of progression to mild cognitive impairment (MCI) and dementia.

Methods: We employed multivariable logistic regression on longitudinal NACC data, to identify drug classes associated with disease progression risk, using clinical diagnosis and CDRSOB as the outcome.

Results: Anticoagulants, non-steroidal anti-inflammatory drugs, antihypertensives, antidepressants, and Parkinson's medications were significantly associated with decreased progression to mild cognitive impairment (MCI)/dementia, and antipsychotics, antidiabetics, hypolipidemic drugs, and Alzheimer's disease (AD) medications were significantly associated with increased progression risk. Associations were however dependant on the diagnostic measure used, e.g., levodopa was associated with reduced MCI-to-AD risk using CDRSOB as the outcome (OR:0.28, FDR $p<0.002$), but not with clinical diagnosis. Additionally, some associations appear to be gender specific; for instance, antiadrenergic agents had lower MCI-to-Dementia risk only for men (OR:0.67, FDR $p<0.001$) using CDRSOB.

Conclusions: Overall, we demonstrate that choice of diagnostic measure can influence the magnitude and significance of risk or protection attributed to drug classes. A consensus must

be reached within the research community with respect to the most accurate diagnostic outcome to identify risk and improve reproducibility.

Funding: This work was supported by the European Union's INTERREG VA Programme, managed by the Special EU Programmes Body (SEUPB (Centre for Personalised Medicine, IVA 5036)), with additional support by the Northern Ireland Functional Brain Mapping Project Facility (1303/101154803), funded by invest Northern Ireland and the University of Ulster (K.W.-L.), Alzheimer's Research UK (ARUK) NI Pump Priming (M.B.,S.T.,K.W.-L.,P.L.M.), Ulster University Research Challenge Fund (M.B.,S.T.,K.W.-L.,M.B.), and the Dr George Moore Endowment for Data Science at Ulster University (M.B.).

## Introduction

Dementia is a complex disease with several subtypes and aetiologies, and few effective therapeutics (Arvanitakis et al., 2019). Therefore, extensive research has been carried out analysing factors that may influence disease incidence and progression (Livingston et al., 2020; Peters et al., 2019). Medications, in particular, may affect cognition in older adults (Barton et al., 2008; Nikaido et al., 1990) due to increased drug sensitivity associated with age-related factors such as impaired liver metabolism and decreased renal function (Barton et al., 2008). Moreover, factors like potentially inappropriate prescribing, drug interactions and polypharmacy, which are common in dementia patients, complicate the assessment of specific drug classes on cognition (Delgado et al., 2019).

Several pharmacoepidemiology studies have analysed the relationship between medications and dementia risk with conflicting findings. Researchers have acknowledged that methodological differences substantially contribute to the variation in risk attributed to different medications. Study design, inclusion criteria, data preparation, and especially the diagnostic criteria used can influence outcomes (Erkinjuntti et al., 1997; Jamsen et al., 2016; Wancata et al., 2007). One study examining antidiabetic medications found protective effects of metformin on dementia risk (Chin-Hsiao 2019), whereas another reported increased risk of cognitive impairment associated with metformin use (Moore et al., 2013). For antihypertensives, one systematic review reported a significant association between reduced dementia risk and use of diuretics and angiotensin-converting enzyme (ACE) inhibitors (Shah et al., 2009), whereas a study by Rouch et al. (2015) showed that calcium ($Ca^{2+}$) channel blockers and renin–angiotensin system blockers, were associated with prevention of dementia. Similarly, discrepant findings across studies have been reported on the association between anxiolytics, such as benzodiazepines, and cognitive decline (Salzman, 2020; Verdoux et al., 2005). This is also the case for other drug classes including antidepressants, antipsychotics, hypolipidemic drugs, and non-steroidal anti-inflammatory (NSAIDs) (Biringer et al., 2009; Hill et al., 2010; Imbimbo et al., 2010; Schulz et al., 2018; Zhang et al., 2018). We note significant variability in the diagnostic criteria used across studies that undoubtedly impacts upon risk attribution leading to conflicting findings.

Clinical assessment of dementia involves detailed examination of medical history, cognitive tests followed by laboratory assays, psychiatric evaluation, and brain imaging to identify dementia subtype. Studies have shown that subtle differences in classification associated with National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA), Diagnostic and

Statistical Manual Of Mental Disorders (DSM) criteria including DSM–III–R, DSM–IV, DSM-V, International Classification of Diseases (ICD) criteria including ICD-9, ICD-10, ICD-11, and Cambridge Mental Disorders of the Elderly Examination (CAMDEX) criteria can influence clinical diagnosis, and lead to variation in dementia prevalence (Berman & Bursztajn 1999; Chaves et al., 2007; Erkinjuntti et al., 1997; Wancata et al., 2007). As a result of this variation, researchers often employ cognitive scores for analysis, especially in longitudinal studies as they allow for identifying small changes in cognition over time. However, in clinical settings cognitive tests are mainly used to aid the diagnostic decision-making process.

The Clinical Dementia Rating (CDR® Dementia Staging Instrument) scale, a cognitive assessment tool, is regularly used in clinical and research settings to gauge dementia severity. It provides a global score, and a more detailed CDR sum of boxes (CDRSOB) score obtained through patient and informant interview based on the following cognitive and functional domains; memory, orientation, judgment & problem solving, community affairs, home & hobbies, and personal care (Morris, 1993). Studies have reported moderate (Forsell et al., 1992; Juva et al., 1994), to good (Chaves et al., 2007; Ding et al., 2018; Lima et al., 2017) correlation of the CDR scale with DSM and McKhann (1984) diagnostic criteria, with one study reporting efficiency of CDRSOB in distinguishing MCI from dementia for patients with CDR global score 0.5 (O'Bryant et al.,2010). However, it is unclear whether such cognitive-functional assessments are consistent with clinical diagnosis in terms of evaluating the benefits or risks of medications.

In this study, we investigated how the associations between medications and dementia risk vary between clinical diagnosis and CDRSOB scores generally, and differentially in men and women (Trenaman et al., 2009). We analysed several drug classes available in the

National Alzheimer's Coordinating Center (NACC) dataset, namely, antihypertensives, lipid lowering medication, NSAIDs, anticoagulants, antidepressants, antipsychotics, anxiolytics, antidiabetics, Alzheimer's disease (AD) medication and Parkinson's disease (PD) medication, and subcategories of drugs within each class, for identifying those significantly associated with progression to MCI, all-cause dementia, and AD.

## Methods

### Data source

Archival data from the National Alzheimer's Coordinating Center (NACC), consisting of over 500 variables on genetic, lifestyle, and clinical features for 39,531 individuals was used in this study. Details about the NACC, recruitment of participants, and assessment process has been previously described (Besser et al., 2018; Morris et al., 2006).

The NACC Uniform Data Set (UDS), comprising of data collected from September 2005 until September 2020 was used in our analysis. The NACC is approved by the University of Washington Institutional Review Board. Written, informed consent from all participants and co-participants included in NACC-UDS was obtained by the Alzheimer's disease research centers (ADRCs) where they completed their study visits. For the purpose of publication patient consent was not required. The following drug classes were analysed: antihypertensives, lipid lowering medication, NSAIDs, anticoagulants/antiplatelets, antidepressants, antipsychotic agents, anxiolytics/sedatives/hypnotics, diabetes medication, AD medication, and Parkinson's disease medication. The diagnostic category of participants was determined based on both clinical diagnosis and CDRSOB scores. In NACC-UDS Version 1

134 and 2, the process of clinical diagnosis for all-cause dementia relied on the diagnostic protocol
135 of the ADRC, with centres generally using DSM-IV (1994) or NINCDS-ADRDA guidelines. In
136 NACC-UDS Version 3, the criteria for all-cause dementia were modified from McKhann (2011).
137 Diagnoses of MCI were established using the modified Petersen criteria. Individuals included
138 in the analyses were aged ≥40 years.

| | **Diagnostic criteria for UDS version 1.0 – 2.0** | **Diagnostic criteria for UDS version 3.0** |
|---|---|---|
| **Mild cognitive impairment (MCI)** | Petersen & Morris, 2005 | Petersen & Morris, 2005 |
| **Alzheimer's disease (AD)** | NINCDS-ADRDA criteria (McKhann et al., 1984) | NIA-AA criteria (McKhann et al., 2011) |
| **All-cause dementia** | Not specified (McKhann et al., 1984 or DSM-IV) | McKhann et al., 2011 |

139

140 **Data preparation**

141 A multi-time-point data preparation approach was employed to conduct progression analysis
142 for reducing bias associated with variables measured at a single time point. The NACC dataset
143 comprises routinely collected data which is updated roughly every three months and the time
144 between visits for individuals ranges from 6 months to ~5 years. However, the majority of
145 participants are followed up every 1-2 years. Clinical diagnosis and CDRSOB scores were
146 identified across all visits for each participant to determine changes in cognitive status over
147 time. Subsequently, six groups were identified, and the following five comparisons were
148 assessed for both diagnostic measures; participants that were healthy across all visits
149 (Remained Healthy), participants that were MCI across all visits (Remained MCI), those who
150 progressed from Healthy-to-MCI, from Healthy-to-AD, from MCI-to-Dementia, and from MCI-

151 to-AD. Individuals with single visits or a fluctuating diagnosis were excluded, and only those

152 with a clear progression trend were analysed. CDRSOB scores were categorized as healthy: 0,

153 MCI: 0.5-4.0 and dementia: 4.5-18 (O'Bryant et al., 2010).

154




155

156 Fig. 1: Data preparation process for progression groups within the NACC dataset. (AD:

157 Alzheimer's Disease; CDRSOB: Clinical Dementia Rating Sum of Boxes; MCI: Mild Cognitive

158 Impairment; NACC: National Alzheimer's Coordinating Center).

159

160 Since covariates like diabetes, traumatic brain injury can occur after baseline,
161 observations across all visits before the individual progressed to MCI/dementia were
162 examined to determine their presence/absence. In the case of education and number of years
163 smoked, the maximum value across all visits before the individual progressed to
164 MCI/dementia was used for analysis. Body mass index (BMI) was categorized as underweight-
165 1 (<18.5 kg/m2), normal-2 (18.5–24.99 kg/m2), or overweight-3 (>24.99 kg/m2).
166 Subsequently, transitions in BMI over time were determined by calculating the average of
167 BMI categories (underweight, normal, or overweight) across all visits and qualitatively
168 comparing this to the baseline category to determine increase/decrease/stable progression
169 (Kaur et al., 2020). Figure 1 depicts the sample selection process for the different progression
170 groups analysed. Details about the multi-time-point analysis approach have been published
171 previously (Kaur et al., 2020).

172 The major drug classes analysed in this study, and subcategories of antihypertensives
173 are available in the UDS dataset as variables. For subcategorising the other significant drug
174 classes, we used the researcher's data dictionary (RDD; Kukull, 2015) to identify the common
175 drug names stored in the UDS. Next, we searched for specific drug terms (Supplementary File
176 1) across all visits to determine prescription data for each individual, those who reported a
177 specific drug at least during one visit were classified as taking the medication. These were
178 then categorised based on their mechanism of action. Medications with ophthalmic and
179 topical routes of administration were excluded from this analysis. Table 1 represents the drug
180 classes and their respective subcategories that were analysed in this study. Surprisingly, it was
181 observed that some cognitively healthy individuals (n=70) were taking AD medication, either

182 a reflection of genuine prescribing patterns for AD drugs or errors at the point of data entry.

183 These data were removed and not analysed.

184 Table 1: Drug classes analysed, and their subcategories based on the mechanism of action.
185 (AD: Alzheimer's Disease; ADP: Adenosine Diphosphate; ACE: Angiotensin-converting
186 enzyme; DPP-4: Dipeptidyl peptidase-4; SGLT-2: Sodium-glucose co-transporter-2; NSAIDs:
187 Nonsteroidal anti-inflammatory drugs; COX-2: Cyclooxygenase-2; COMT: Catechol-O-
188 methyltransferase; MAO-B: Monoamine oxidase type B).

| AD medication | Anticoagulants/ Antiplatelets | Lipid lowering drugs | Antihypertensives | Diabetes medication |
|---|---|---|---|---|
| - Donepezil<br>- Memantine<br>- Galantamine<br>- Rivastigmine<br>- Tacrine<br>- Donepezil + memantine combination | - Heparin group<br>- Vitamin K antagonist<br>- Direct Xa inhibitors<br>- Direct thrombin (IIa) inhibitors<br>- Phosphodiesterase inhibitors<br>- ADP receptor/ P2Y12 inhibitors<br>Aspirins | - Statins<br>- Niacin<br>- Fibrates<br>- Bile acid sequestrants<br>- Ezetimibe<br>- Combination therapy | - Antihypertensive combination therapy<br>- ACE inhibitor<br>- Antiadrenergic agent<br>- Beta blocker<br>- Calcium channel blocker<br>- Diuretic<br>- Vasodilator<br>- Angiotensin II inhibitor | - Sulfonylureas<br>- DPP-4 inhibitors<br>- Combination drugs<br>- SGLT-2 inhibitors<br>- Thiazolidinediones<br>- Alpha-glucosidase inhibitors<br>- Biguanides<br>- Insulin<br>- Incretin mimetics<br>- Meglitinides |
| | | | | |
| **Antipsychotic agents** | **Anxiolytics** | **NSAIDS** | **Parkinson's medications** | **Antidepressants** |

| | | | | |
|---|---|---|---|---|
| - Lithium<br>- Tricyclics<br>- Phenothiazines<br>- Benzisoxazole/ benzisothiazoles<br>- Phenylpiperazines/ quinolinones<br>- Combination therapy | - Barbiturates<br>- Benzodiazepines<br>- Antihistamines<br>- Sedatives/ Hypnotics<br>- Azapirone | - Salicylates<br>- Propionic acid derivatives<br>- Enolic acid derivatives<br>- Selective COX-2 inhibitors<br>- Acetic acid derivatives | - Dopamine precursor<br>- Dopamine receptor agonist<br>- Anticholinergics<br>- COMT inhibitors<br>- MAO-B inhibitors | - Selective serotonin reuptake inhibitors<br>- Serotonin antagonist and reuptake inhibitors<br>- Serotonin and norepinephrine reuptake inhibitors<br>- Tricyclic antidepressants<br>- Tetracyclic antidepressants<br>- Norepinephrine-dopamine reuptake inhibitors<br>- Serotonin modulator and stimulator<br>- Combination therapy |

**Statistical analysis**

Shapiro-Wilk test was employed to assess normality of data for demographic analysis. In the case of continuous variables, significance of differences was evaluated using an independent t-test for normally distributed data, and the Mann-Whitney U test for non-normally distributed data. For categorical variables, a chi-square test was applied compare differences.

In order to explore the associations between different drug classes and disease progression, multivariable logistic regression was employed (Glonek et al., 1995). Major drug classes were first analysed together, followed by analysis of their subcategories (Table 1). Additionally, the analysis was repeated for men and women separately, to determine sex-specific effects associated with drug exposure. The analyses were adjusted for important confounders and risk factors of dementia including age, sex, race, years of education and smoking, alcoholism, hypertension, diabetes, cardiovascular disorders, depression, BMI, traumatic brain injury, and hearing impairment (Livingston et al., 2020). Additionally, to

203 determine whether significant associations occur due to the medication or the underlying
204 condition, respective comorbidities were also included in the analysis, for e.g., Parkinson's
205 disease (PD) for analysing PD medications, schizophrenia and bipolar disorder for analysing
206 antipsychotics.

207 Sensitivity analysis was performed by analysing individuals who reported a specific
208 drug at least during two visits. Adjustment for multiple hypothesis testing was achieved by
209 applying false discovery rate (FDR) using the Benjamini-Yekutieli correction method
210 (Benjamini & Yekutieli, 2001). FDR adjusted p-values (FDR p) <0.01 were considered
211 statistically significant.

212

213 **Software and codes**

214 Statistical analyses were performed using the 'PredictABEL' package in R studio (Version
215 1.1.423) on a Windows machine with eight memory cores. Codes are available on GitHub
216 (web link to be made publicly available upon acceptance of manuscript).

217

218 ## Results

219 **General characteristics**

220 The average follow-up time for the groups analysed using clinical diagnosis (CDRSOB) was
221 4.92 (4.86) years for stable healthy, 5.82 (5.65) years for Healthy-to-MCI, 2.65 (2.94) years for
222 stable MCI, 6.4 (6.88) years for Healthy-to-Dementia, and 3.65 (3.8) years for MCI-to-
223 Dementia progression group.

Analysis revealed that individuals who progressed from Healthy-to-MCI and from Healthy-to-Dementia were less likely to be married ($p=0.01$, $p=0.01$, respectively), a higher proportion of them suffered from conditions like hypertension ($p<0.0001$, $p<0.0001$, respectively), cardiovascular disorders ($p<0.0001$, $p<0.0001$, respectively), depression ($p<0.05$, $p<0.0001$, respectively), and hearing impairment ($p<0.0001$, $p<0.0001$, respectively), and they had a higher average of total years smoked compared to stable healthy individuals ($p<0.05$, $p=0.001$, respectively). Those who progressed from Healthy-to-Dementia were also significantly less educated ($p<0.0001$), and a higher proportion of them reported decrease in BMI over time compared to stable healthy individuals ($p<0.0001$).

Compared to the stable MCI group, those who progressed from MCI-to-Dementia were more likely to be married ($p<0.0001$), a higher proportion of them suffered from depression ($p<0.05$) and hearing impairment ($p<0.05$), and a lower proportion suffered from diabetes ($p<0.001$) and hypertension ($p<0.0001$). Detailed results can be found in Supplementary File 2.

**Medication analysis**

Using multivariable logistic regression, we identified drug classes associated with risk of progression from Healthy-to-MCI, Healthy-to-Dementia, MCI-to-Dementia, and MCI-to-AD for both CDRSOB and clinical diagnosis as the outcome. The adjusted odds ratios were calculated based on drug exposure vs. absence of the drug of interest during the timeline available within the NACC dataset. For brevity, significant results are illustrated in Figures 2-5. Complete results, including the insignificant associations, can be found in Supplementary File 3.

247

248 **Parkinson's medications are associated with reduced MCI-to-AD progression risk in men**

249 Comparing stable MCI individuals to those who progressed from MCI-to-
250 Dementia/AD, anxiolytics were significantly associated with decreased progression risk
251 overall, and in men and women separately only with CDRSOB scores as the outcome (FDR
252 p<0.01; Fig. 2). Parkinson's medications on the other hand, were associated with reduced
253 MCI-to-AD risk overall (FDR p<0.01), and specifically for men (FDR p<0.01) with both clinical
254 diagnosis and CDRSOB scores as the outcome (Fig. 2). None of the major drug classes analysed
255 were significantly associated with risk of progression from Healthy-to-MCI or Healthy-to-
256 Dementia/AD.

257




258

Fig. 2: Summary grouped forest plots of adjusted odds ratios for drug classes significantly associated with risk of progression to dementia and AD for two diagnostic variables; clinical diagnosis and CDRSOB scores. (AD: Alzheimer's Disease; MCI: Mild Cognitive Impairment; CDRSOB: Clinical Dementia Rating sum of boxes; CI: Confidence Intervals). *$*p<0.05$, $**p<0.01$, $***p<0.001$, $****p<0.0001$*.

**Antiadrenergic agents are associated with reduced MCI to dementia progression risk in men**

We then focused on analysis of subcategories of the drug families. In terms of anticoagulants, direct Xa inhibitors were significantly associated with reduced Healthy-to-MCI risk (FDR p=0.001) overall with CDRSOB as the outcome (Fig. 3A). They were also associated with reduced MCI-to-Dementia and MCI-to-AD risk with CDRSOB as the outcome, however with a lower significance level (FDR p<0.05; Fig. 3A). Dopamine precursors that are used to treat Parkinson's disease, were significantly associated with reduced MCI-to-AD risk overall (FDR p<0.01) and specifically in men with CDRSOB as the outcome (FDR p<0.05; Fig. 3A). Furthermore, antiadrenergic agents, a type of antihypertensive medication, were associated with reduced MCI-to-Dementia and MCI-to-AD risk overall (FDR p<0.001), and specifically in men with CDRSOB as the outcome (FDR p<0.01; Fig. 3B).

While analysing subcategories of NSAIDs, selective COX-2 inhibitors were associated with reduced MCI-to-Dementia and MCI-to-AD risk overall with clinical diagnosis as the outcome (FDR p<0.05; Fig. 3B). In terms of antidepressants, Serotonin antagonist and reuptake inhibitors (SARIs; FDR p<0.01) and Norepinephrine-dopamine reuptake inhibitors (NDRIs; FDR p<0.05) were significantly associated with reduced MCI-to-Dementia and MCI-to-AD progression risk overall with CDRSOB as the outcome (Fig. 3C). Further, SARIs and

282 tricyclic antidepressants were associated with reduced MCI-to-Dementia risk in men with
283 CDRSOB as the diagnostic outcome (FDR p<0.05; Fig. 3C).

284 Cardiovascular disorders, hypertension, and depression are known to be associated
285 with impaired cognition. The difference in significance observed between CDRSOB and clinical
286 diagnosis for these drug classes may represent improved cognition associated with drug
287 treatment, however these medications may not play a role in reducing the risk of dementia.
288 In the case of dopamine precursors, co-occurrence of AD and PD is infrequent, however
289 similar cognitive-functional domains are affected in both disorders which might explain the
290 significant results obtained with CDRSOB scores (Fig. 3B).

291




292







Fig. 3: Summary grouped forest plots of adjusted odds ratios for drug subcategories significantly associated with reduced risk of progression to MCI, dementia, and AD for two

297 diagnostic variables; clinical diagnosis and CDRSOB scores. Drug classes analysed: (A)
298 Anticoagulants and Parkinson's medication; (B) Antihypertensives and NSAIDs; (C)
299 Antidepressants. (AD: Alzheimer's Disease; CDRSOB: Clinical Dementia Rating sum of boxes;
300 CI: Confidence Intervals; COX: Cyclooxygenase-2; MCI: Mild Cognitive Impairment; NDRIs:
301 Norepinephrine-dopamine reuptake inhibitors; SARIs: Serotonin antagonist and reuptake
302 inhibitors). *$*p<0.05$, $**p<0.01$, $***p<0.001$, $****p<0.0001$.*

303

304

305

306 **Combination hypolipidemic therapy and thiazolidinediones are associated with increased**
307 **MCI-to-AD risk with CDRSOB as outcome**

308 Analysis of lipid lowering drugs revealed that combination therapy was associated
309 with increased MCI-to-Dementia and MCI-to-AD risk with CDRSOB as the outcome (FDR
310 $p<0.05$; Fig. 4). Additionally, in the case of antidiabetic medication, thiazolidinediones were
311 associated with increased MCI-to-AD risk with CDRSOB as the diagnostic measure (FDR
312 $p<0.05$; Fig. 4).

313




Fig. 4: Summary grouped forest plots of adjusted odds ratios for drug subcategories significantly associated with increased risk of progression to dementia and AD for two diagnostic variables; clinical diagnosis and CDRSOB scores. Drug classes analysed: Hypolipidemic agents and Diabetes medication. (AD: Alzheimer's Disease; CDRSOB: Clinical Dementia Rating sum of boxes; CI: Confidence Intervals; MCI: Mild Cognitive Impairment). *$*p<0.05$.*

**AD drug treatments in individuals with MCI are associated with increased risk of dementia and AD**

Commonly prescribed AD medications were analysed in participants who remained MCI over time vs. those who progressed from MCI to AD specifically or dementia in general. Donepezil, a cholinesterase inhibitor (ChEI) was significantly associated with increased MCI-to-Dementia risk (FDR $p<0.001$; Fig. 5A) and MCI-to-AD risk (FDR $p<0.001$; Fig. 5B) in general,

328 and in men and women with both clinical diagnosis and CDRSOB as the outcome. Similarly,
329 memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist was also significantly
330 associated with increased MCI-to-Dementia and MCI-to-AD risk overall and for men and
331 women with both clinical diagnosis and CDRSOB (FDR $p<0.001$; Fig. 5).

332 Galantamine and Rivastigmine (both ChEIs), were associated with increased MCI-to-
333 Dementia and MCI-to-AD progression risk in general (FDR $p<0.001$), and for both men and
334 women with CDRSOB as the diagnostic measure, but not clinical diagnosis (Fig. 5).

335 In the NACC dataset, more individuals are classified as MCI or dementia with CDRSOB
336 scores as compared to clinical diagnosis (Fig. 5). Further, higher proportion of individuals are
337 prescribed donepezil/memantine compared to galantamine/rivastigmine which may explain
338 the difference in significance of results for the latter while comparing the two diagnostic
339 outcomes.


A
Remained MCI vs. MCI-to-Dementia
Clinical Diagnosis
CDRSOB
Odds Ratio (95% CI) FDR p
Odds Ratio (95% CI) FDR p
Combined cohort:
Donepezil
Memantine
Galantamine
Rivastigmine
Men:
Donepezil
Memantine
Galantamine
Rivastigmine
Women:
Donepezil
Memantine
Galantamine
Rivastigmine
Remained MCI (n=2173) vs. MCI-to-Dementia (n=1146)
Remained MCI (n=4207) vs. MCI-to-Dementia (n=1935)
1.98 (1.67-2.34) ****
2.42 (2.13-2.73) ****
1.79 (1.42-2.24) ****
1.75 (1.52-2.02) ****
1.53 (1.04-2.26) 0.36
2.48 (1.91-3.22) ****
1.32 (0.94-1.86) 1
1.73 (1.38-2.16) ****
Remained MCI (n=1094) vs. MCI-to-Dementia (n=623)
Remained MCI (n=2112) vs. MCI-to-Dementia (n=1047)
2.06 (1.65-2.57) ****
2.41 (2.04-2.85) ****
1.66 (1.23-2.24) *
1.56 (1.29-1.89) ****
1.70 (1.02-2.82) 0.05
2.96 (2.08-4.20) ****
1.67 (1.07-2.60) 0.32
1.64 (1.22-2.20) *
Remained MCI (n=1079) vs. MCI-to-Dementia (n=523)
Remained MCI (n=2095) vs. MCI-to-Dementia (n=888)
1.88 (1.45-2.44) ****
2.41 (2.01-2.90) ****
1.99 (1.41-2.84) **
1.99 (1.61-2.48) ****
1.31 (0.71-2.40) 1
1.95 (1.31-2.92) *
0.93 (0.53-1.63) 1
1.90 (1.35-2.69) **
0.5
1.0
2.0
4.0
Odds Ratio (95% CI)

340


B
Remained MCI vs. MCI-to-AD
Clinical Diagnosis
CDRSOB
Odds Ratio (95% CI) FDR p
Odds Ratio (95% CI) FDR p
Combined cohort:
Donepezil
Memantine
Galantamine
Rivastigmine
Men:
Donepezil
Memantine
Galantamine
Rivastigmine
Women:
Donepezil
Memantine
Galantamine
Rivastigmine
Remained MCI (n=2173) vs. MCI-to-AD (n=932)
Remained MCI (n=4207) vs. MCI-to-AD (n=1600)
2.23 (1.86-2.66) ****
2.75 (2.40-3.14) ****
1.88 (1.48-2.38) ****
1.81 (1.56-2.10) ****
1.54 (1.02-2.33) 0.54
2.61 (1.98-3.45) ****
1.25 (0.86-1.82) 1
1.82 (1.43-2.31) ****
Remained MCI (n=1094) vs. MCI-to-AD (n=484)
Remained MCI (n=2112) vs. MCI-to-AD (n=825)
2.42 (1.90-3.08) ****
2.77 (2.31-3.33) ****
1.77 (1.29-2.44) **
1.65 (1.35-2.02) ****
1.74 (1.00-3.01) 0.50
3.06 (2.09-4.46) ****
1.65 (1.02-2.69) 0.50
1.71 (1.24-2.36) *
Remained MCI (n=1079) vs. MCI-to-AD (n=448)
Remained MCI (n=2095) vs. MCI-to-AD (n=775)
2.03 (1.55-2.67) ****
2.70 (2.22-3.28) ****
2.03 (1.41-2.93) **
1.99 (1.59-2.49) ****
1.28 (0.68-2.43) 1
2.18 (1.44-3.29) **
0.83 (0.41-1.52) 1
1.99 (1.39-2.86) **
0.5
1.0
2.0
4.0
Odds Ratio (95% CI)

341

342 Fig. 5: Summary grouped forest plots of adjusted odds ratios for AD drugs significantly
343 associated with risk of progression to dementia and AD for two diagnostic variables; clinical
344 diagnosis and CDRSOB scores. Progression groups analysed: (A) Remained MCI vs. MCI-to-
345 Dementia; (B) Remained MCI vs. MCI-to-AD. (AD: Alzheimer's Disease; CDRSOB: Clinical
346 Dementia Rating sum of boxes; CI: Confidence Intervals; MCI: Mild Cognitive Impairment).
347 **p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.*

348

349 **Sensitivity Analysis**

350 A more conservative approach was adapted for performing sensitivity analysis by only
351 including individuals who reported a specific medication during at least two visits. The results
352 obtained from sensitivity analysis were in accordance with the primary analysis. Anxiolytics
353 (OR: 0.58, FDR p<0.01) and PD medications (OR: 0.26, FDR p<0.001) were significantly
354 associated with reduced MCI-to-AD risk. Direct Xa inhibitors were associated with reduced
355 Healthy-to-MCI risk (OR: 0.58, FDR p<0.01). Antiadrenergics (OR: 0.71, FDR p=0.04) and SARIs
356 (OR: 0.52, FDR p<0.01) were associated with reduced MCI-to-Dementia risk. Further,
357 dopamine precursors were associated with reduced MCI-to-AD risk (OR: 0.09, FDR p=0.03).
358 Sensitivity analysis of AD medications also revealed significant results that were in accordance
359 with the primary analysis for both CDRSOB and clinical diagnosis (Supplementary File 3).

360 In the case of selective COX-2 inhibitors, NDRIs, tricyclic antidepressants,
361 hypolipidemic combination therapy, and thiazolidinediones which had FDR p<0.05 in the
362 primary analysis (Figures 3-4), results from sensitivity analysis, although not statistically

363 significant were qualitatively similar to the primary analysis. The detailed regression results
364 can be found in Supplementary File 3.

365

## 366 Discussion

367 In this study, we demonstrate that the use of different diagnostic measures for MCI and
368 dementia, i.e., clinical diagnosis and CDRSOB scores, affect the significance of the association
369 of various medications with disease risk and progression. From the drug classes analysed,
370 anxiolytics and Parkinson's Disease (PD) medications were found to be differentially
371 associated with risk of progression to all-cause dementia and AD with respect to the
372 diagnostic measure used. Additionally, subcategories of drug classes including direct Xa
373 inhibitors, dopamine precursors, antiadrenergic agents, selective COX-2 inhibitors, SARIs,
374 NDRIs, and tricyclic antidepressants were associated with decreased progression risk,
375 whereas combination hypolipidemic therapy and thiazolidinediones were associated with
376 increased progression risk.

377 In the NACC dataset, consensus-based clinical diagnosis was made using the criteria
378 proposed by McKhann et al. (Mckhann et al., 1984; Mckhann et al., 2011). A previous study,
379 analysing the NACC dataset, reported diagnostic accuracy with 0.71 sensitivity and 0.81
380 specificity when comparing CDRSOB scores to dementia diagnosis (O'Bryant et al., 2010). We
381 report that despite good correlation between the two diagnostic measures (Ding et al., 2018),
382 our analysis produced discordant results while analysing risk associated with different
383 medications. Whilst odds ratios were consistently in the same direction, the statistical
384 significance of results was inconsistent for the two diagnostic measures.

385 The CDRSOB scale offers a wider score range allowing better demarcation of subtle
386 changes between different stages of disease progression. In the NACC cohort, a lower number
387 of individuals are classified into Healthy-to-MCI group by clinical diagnosis (n=791), compared
388 to CDRSOB score (n=1184; Fig. 1). This suggests that CDRSOB scale can detect early disease
389 symptoms and help diagnose MCI. Whereas in terms of a clinical diagnosis, there are no
390 specific tests that confirm MCI, judgement is made based on clinical evaluation and exclusion
391 of other causative factors such as hypothyroidism or vitamin B12 deficiency. These factors
392 not only affect the prevalence of MCI and dementia in a cohort but may also lead to variation
393 in risk analysis.

394 In our study, PD medications were significantly associated with reduced MCI-to-AD
395 risk overall, and specifically for men given that PD is more common in males, with CDRSOB as
396 the outcome (FDR $p<0.0001$). Dopamine precursors, in particular, were associated with
397 significantly reduced MCI-to-AD risk with CDRSOB as the outcome. Studies have shown that
398 levodopa treatment can have beneficial effect on cognition (Ikeda et al., 2017). Additionally,
399 PD related MCI is clinically distinct and has a longer conversion period to dementia, compared
400 to AD related MCI (Besser et al., 2016). In the case of anxiolytics, while they were significantly
401 associated with reduced MCI-to-AD progression risk (Fig. 2), analysis of its subclasses did not
402 reveal any significant results. However, anxiety itself was associated with reduced MCI-to-AD
403 risk (OR: 0.54, FDR $p<0.05$; Supplementary File 3).

404 Direct factor Xa inhibitors, which are prescribed for treatment and prevention of blood
405 clots and strokes were significantly associated with reduced Healthy-to-MCI and MCI-to-
406 Dementia/AD risk. These results are in accordance with several published studies that found
407 reduced risk of cognitive impairment and dementia associated with oral anticoagulants

408 (Cheng et al., 2018; Ding et al., 2018; Zeng et al., 2019). Direct Xa inhibitors in particular are
409 associated with lower dementia risk compared to other anticoagulants (Lee et al., 2021).

410 Antiadrenergic agents were significantly associated with reduced MCI-to-
411 Dementia/AD risk overall, and specifically for men with CDRSOB scores (FDR $p<0.01$). Several
412 studies have reported increased risk of cognitive impairment associated with hypertension,
413 and a subsequent reduced risk with antihypertensive treatment (Ding et al., 2020; Shah et al.,
414 2009). Although there is ambiguity regarding the duration, specific drug subclass, and optimal
415 dosage to prevent cognitive impairment (Ou et al., 2020). A previous study analysing the
416 NACC dataset reported lower cognitive scores associated with lower systolic BP (Fiford et al.,
417 2020). Analysis of antidepressants revealed significant association of SARIs with reduced MCI-
418 to-Dementia/AD progression risk (FDR $p<0.01$). While depression had an OR value of 1.32
419 (FDR $p<0.001$) suggesting that it is associated with increased risk of progression, however,
420 treatment of the disorder with certain antidepressants can protect against this risk. Studies
421 have suggested that SARIs like trazodone exhibit neuroprotective properties when examined
422 in mammalian cell cultures and in neurodegenerative mouse models (Halliday et al., 2017)
423 with complex cellular signalling pathway mechanisms (Joshi et al., 2020).

424 With respect to NSAIDs, conflicting outcomes have been reported in observational and
425 experimental studies (Ali et al., 2019; Breitner et al., 2009; Cote et al., 2012). Our analysis
426 showed reduced MCI-to-Dementia/AD risk associated with selective COX-2 inhibitors while
427 using clinical diagnosis. These results are in accordance with preclinical studies that found
428 beneficial effects of selective COX-2 inhibitors on memory and synaptic plasticity, as it has
429 been shown to hinder the neurotoxic effects of amyloid beta (Kotilinek et al., 2008; Woodling
430 et al., 2016). NSAID use may also lead to modulation of inflammatory pathways which can be

431 beneficial as inflammatory genes and molecules have been linked with AD development
432 (Newcombe et al., 2018; Raj et al., 2017). Additionally, studies have shown that some NSAIDs
433 can mediate Aβ clearance. However, it is only effective during the early disease stages
434 (Imbimbo et al., 2010).

435 We found that thiazolidinediones were associated with increased MCI-to-AD risk with
436 CDRSOB as the outcome (FDR $p<0.05$). Despite the association of diabetes with lower
437 cognitive function, several studies have reported a reduced dementia risk in those taking oral
438 hypoglycaemic medication (Hsu et al., 2011; Kim et al., 2019; Wu et al., 2020). However, in
439 the case of thiazolidinediones, drug exposure has been associated with faster cognitive
440 decline and poorer immediate memory (Seaquist et al., 2013; Wu et al., 2020). Increased risk
441 of dementia linked to intensive diabetes treatment leading to hypoglycaemia has also been
442 reported (Zammitt & Frier, 2005). In terms of lipid lowering drugs, statin combination therapy
443 was also associated with increased MCI-to-Dementia progression risk with CDRSOB (FDR
444 $p<0.05$).

445 While focusing on specific AD drugs for MCI-to-Dementia and MCI-to-AD progression,
446 donepezil and memantine were significantly associated with increased risk of disease
447 progression with both clinical diagnosis and CDRSOB as the outcome. However, galantamine
448 and rivastigmine were found to be significantly associated only with CDRSOB as the outcome.
449 Previous studies have shown faster cognitive decline with ChEI therapy in MCI and early AD
450 (Han et al., 2019; Schneider et al., 2011). These associations could be due to confounding by
451 indication since patients with cognitive impairment are more likely to be prescribed these
452 drugs. It also reflects the prescribing patterns across clinics since, in contradiction to the US

453 FDA guidelines, physicians are known to prescribe ChEIs and memantine during early stages
454 of impairment (Schneider et al., 2011).

455 Overall, our study shows that the magnitude and significance of association of
456 different medications with disease progression can vary depending on the diagnostic measure
457 used. CDRSOB scores, though comparatively less comprehensive, form a part of clinical
458 diagnosis which leads to high correlation between the two. Due to unavailability of clinical
459 diagnosis in some datasets, or a preference for more quantitative analysis to increase
460 precision and reduce subjectivity, researchers often opt for cognitive scores (Bucholc et al.,
461 2019; Ding et al., 2018; McCombe et al., 2022). However, we must be aware of the
462 implications of choosing a particular diagnostic measure and be careful regarding how we
463 interpret the results.

464 There were limitations in this study, such as the low number of individuals while
465 analysing subcategories of drug classes. Importantly, it should be noted that significant results
466 obtained in this study are associations and not causation, as the data was not generated from
467 randomised controlled trials. Therefore, our findings are vulnerable to unmeasured
468 confounders or confounding by indication, with AD drugs for example. Moreover, in this study
469 exposure to the drug classes was analysed irrespective of duration, dosage, and drug-drug
470 interactions. To address these issues there is a need for more detailed studies on larger
471 cohorts with data on dosage, that will allow analysis of specific drug classes individually, while
472 making use of comprehensive drug interaction databases like DDInter (Xiong et al., 2022).
473 Undoubtedly, further studies are required to identify the most relevant diagnostic measure
474 and to inform prescribing patterns in order to reduce modifiable risk of dementia.
475 Additionally, based on our results we believe that further studies should focus on a gender

476 stratified approach as there may be differential risk profiles associated with various
477 subcategories of drug classes in men and women.

478

## 479 Legends for Supplementary Files

480 Supplementary File 1: Medication terms used for identifying drug exposure across patient
481 visits, split by drug classes and drug subcategories.

482 Supplementary File 2: Demographic characteristics of stable and progression groups analysed
483 with clinician diagnosis and CDRSOB scores as diagnostic outcomes.

484 Supplementary File 3: Detailed regression results

485 Supplementary Table 3A: Detailed regression results for stable Healthy vs. Healthy-to-MCI
486 analysis (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).

487 Supplementary Table 3B: Detailed regression results for stable Healthy vs. Healthy-to-
488 Dementia analysis (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).

489 Supplementary Table 3C: Detailed regression results for stable Healthy vs. Healthy-to-AD
490 analysis (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).

491 Supplementary Table 3D: Detailed regression results for stable MCI vs. MCI-to-Dementia
492 analysis (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).

493 Supplementary Table 3E: Detailed regression results for stable Healthy vs. MCI vs. MCI-to-AD
494 analysis (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).

495

## Acknowledgements

1. This work was supported by the European Union's INTERREG VA Programme, managed by the Special EU Programmes Body (SEUPB (Centre for Personalised Medicine, IVA 5036)), with additional support by the Northern Ireland Functional Brain Mapping Project Facility (1303/101154803), funded by invest Northern Ireland and the University of Ulster (K.W.-L.), Alzheimer's Research UK (ARUK) NI Pump Priming (M.B.,S.T.,K.W.-L.,P.L.M.), Ulster University Research Challenge Fund (M.B.,S.T.,K.W.-L.,M.B.), and the Dr George Moore Endowment for Data Science at Ulster University (M.B.). The views and opinions expressed in this paper do not necessarily reflect those of the European Commission or the SEUPB.

2. The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA-funded ADCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P50 AG047266 (PI Todd Golde, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Thomas Wisniewski, MD), P30 AG013854 (PI M. Marsel Mesulam, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P50 AG047366 (PI Victor Henderson, MD, MS), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG005131 (PI James Brewer, MD, PhD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30AG053760 (PI Henry Paulson, MD, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P30 AG049638 (PI Suzanne Craft, PhD), P50 AG005136 (PI Thomas Grabowski, MD), P50

AG033514 (PI Sanjay Asthana, MD, FRCP), P50 AG005681 (PI John Morris, MD), P50 AG047270 (PI Stephen Strittmatter, MD, PhD).”

538 **References**

539 Ali, M.M., Ghouri, R.G., Ans, A.H., Akbar, A. & Toheed, A. 2019, "Recommendations for Anti-
540 inflammatory Treatments in Alzheimer's Disease: A Comprehensive Review of the Literature",
541 Cureus, vol. 11, no. 5, pp. e4620.

542 American Psychiatric Association.1994, “Diagnostic and statistical manual of mental
543 disorders: DSM-IV” Washington, pp.866.

544 Arvanitakis, Z., Shah, R.C., Bennett, D.A. 2019, “Diagnosis and Management of Dementia:
545 Review”, JAMA, vol. 322, no. 16, pp. 1589-1599.

546 Barton C., Sklenicka J., Sayegh P. & Yaffe, K. 2008, "Contraindicated medication use among
547 patients in a memory disorders clinic.", American Journal Geriatric Pharmacotherapy, vol. 6,
548 no. 3, pp. 147-152.

549 Benjamini, Y. & Yekutieli, D. 2001, "The Control of the False Discovery Rate in Multiple Testing
550 under Dependency", The Annals of Statistics, vol. 29, no. 4, pp. 1165-1188.

551 Berman, S., Bursztajn, H.J. 1999, “Clinical criteria for three types of dementia had low
552 sensitivity and high specificity.” Evidence-Based Mental Health, vol. 2, pp. 91.

553 Besser, L., Kukull, W., Knopman, D.S., Chui, H., Galasko, D., Weintraub, S., Jicha, G., Carlsson,
554 C., Burns, J., Quinn, J., Sweet, R.A., Rascovsky, K., Teylan, M., Beekly, D., Thomas, G.,
555 Bollenbeck, M., Monsell, S., Mock, C., Zhou, X.H., Thomas, N., Robichaud, E., Dean, M.,
556 Hubbard, J., Jacka, M., Schwabe-Fry, K., Wu, J., Phelps, C., Morris, J.C. & Neuropsychology
557 Work Group, Directors,and Clinical Core leaders of the National Institute on Aging-funded US
558 Alzheimer's Disease Centers 2018, "Version 3 of the National Alzheimer's Coordinating

559 Center's Uniform Data Set", Alzheimer Disease & Associated Disorders, vol. 32, no. 4, pp. 351-
560 358.

561 Besser L.M., Litvan I., Monsell S.E., Mock C., Weintraub S., Zhou X.H. & Kukull, W. 2016, "Mild
562 cognitive impairment in Parkinson's disease versus Alzheimer's disease.", Parkinsonism and
563 Related Disorders, vol. 27, pp. 54-60.

564 Biringer, E., Rongve, A. & Lund, A. 2009, "A Review of Modern Antidepressants' Effects on
565 Neurocognitive Function", Current Psychiatry Reviews, vol. 5, no. 3, pp. 164-174.

566 Breitner, J.C.S., Haneuse, S.J.P.A., Walker, R., Dublin, S., Crane, P.K., Gray, S.L. & Larson, E.B.
567 2009, "Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based
568 cohort SYMBOL SYMBOL", Neurology, vol. 72, no. 22, pp. 1899-1905.

569 Bucholc, M., Ding, X., Wang, H., Glass, D. H., Wang, H., Prasad, G., Maguire, L. P., Bjourson, A.
570 J., McClean, P. L., Todd, S., Finn, D. P., & Wong-Lin, K. (2019). A practical computerized
571 decision support system for predicting the severity of Alzheimer's disease of an individual.
572 Expert systems with applications, 130, 157–171.

573 Cheng, W., Liu, W., Li, B., & Li, D. (201. Relationship of Anticoagulant Therapy With Cognitive
574 Impairment Among Patients With Atrial Fibrillation: A Meta-Analysis and Systematic Review.
575 Journal of cardiovascular pharmacology, 71(6), 380–387.

576 Chin-Hsiao, T. 2019, "Metformin and the Risk of Dementia in Type 2 Diabetes Patients.", Aging
577 & Disease, vol. 10, no. 1, pp. 37-48.

578 Chaves, M.L.F., Camozzato, A.L., Godinho, C., Kochhann, R., Schuh, A., de Almeida, V.L. &
579 Kaye, J. 2007, "Validity of the clinical dementia rating scale for the detection and staging of

580 dementia in Brazilian patients.", Alzheimer Disease & Associated Disorders, vol. 21, no. 3, pp.
581 210-217.

582 Cote S., Carmichael P.H., Verreault R., Lindsay J., Lefebvre J. & Laurin, D. 2012, "Nonsteroidal
583 anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer's disease.",
584 Alzheimer's and Dementia, vol. 8, no. 3, pp. 219-226.

585 Delgado, J., Bowman, K. & Clare, L. 2020, "Potentially inappropriate prescribing in dementia:
586 a state-of-the-art review since 2007", BMJ Open, vol. 10, no. 1, pp. e029172.

587 Ding, J., Davis-Plourde, K. L., Sedaghat, S., Tully, P. J., Wang, W., Phillips, C., Pase, M. P., Himali,
588 J. J., Gwen Windham, B., Griswold, M., Gottesman, R., Mosley, T. H., White, L., Guðnason, V.,
589 Debette, S., Beiser, A. S., Seshadri, S., Ikram, M. A., Meirelles, O., Tzourio, C., … Launer, L. J.
590 (2020). Antihypertensive medications and risk for incident dementia and Alzheimer's disease:
591 a meta-analysis of individual participant data from prospective cohort studies. The Lancet.
592 Neurology, 19(1), 61–70.

593 Ding, M., Fratiglioni, L., Johnell, K., Santoni, G., Fastbom, J., Ljungman, P., Marengoni, A., &
594 Qiu, C. 2018. Atrial fibrillation, antithrombotic treatment, and cognitive aging: A population-
595 based study. Neurology, 91(19), e1732–e1740.

596 Ding, X., Bucholc, M., Wang, H., Glass, D.H., Wang, H., Clarke, D.H., Bjourson, A.J., Dowey,
597 L.R.C., O'Kane, M., Prasad, G., Maguire, L. & Wong-Lin, K. 2018, "A hybrid computational
598 approach for efficient Alzheimer's disease classification based on heterogeneous data.",
599 Scientific Reports, vol. 8, no. 1, pp. 9774.

600 Erkinjuntti, T., Ostbye, T., Steenhuis, R. & Hachinski, V. 1997, "The effect of different
601 diagnostic criteria on the prevalence of dementia.", New England Journal of Medicine, vol.
602 337, no. 23, pp. 1667-1674.

603 Fiford C.M., Nicholas J.M., Biessels G.J., Lane C.A., Cardoso M.J. & Barnes, J. 2020, "High blood
604 pressure predicts hippocampal atrophy rate in cognitively impaired elders.", Alzheimer's and
605 Dementia: Diagnosis, Assessment and Disease Monitoring, vol. 12, no. 1) (pagination, pp. Arte
606 Number: e12035. ate of Pubaton: 2020.

607 Fink, H.A., Jutkowitz, E., McCarten, J.R., Hemmy, L.S., Butler, M., Davila, H.M.P.A., Ratner, E.,
608 Calvert, C., Barclay, T.R., Brasure, M.M.S.P.H., M.L.I.S., Nelson, V.A. & Kane, R.L. 2018,
609 "Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and
610 Clinical Alzheimer-Type Dementia: A Systematic Review", Annals of Internal Medicine, vol.
611 168, no. 1, pp. 39-51.

612 Gallacher, J., Elwood, P., Pickering, J., Bayer, A., Fish, M. & BenShlomo, Y. 2012,
613 "Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study
614 (CaPS)", Journal of Epidemiology & Community Health, vol. 66, no. 10, pp. 869-873.

615 Glonek, G.F.V., McCullagh, P. 1995, “Multivariate Logistic Models.” Journal of the Royal
616 Statistical Society, vol. 57, pp. 533-546.

617 Halliday, M., Radford, H., Zents, K., Molloy, C., Moreno, J. A., Verity, N. C., Smith, E., Ortori, C.
618 A., Barrett, D. A., Bushell, M., & Mallucci, G. R. 2017. Repurposed drugs targeting eIF2α-P-
619 mediated translational repression prevent neurodegeneration in mice. Brain : a journal of
620 neurology, 140(6), 1768–1783.

621 Han, J., Besser, L.M.M.S.P.H., Xiong, C., Kukull, W.A. & Morris, J.C. 2019, "Cholinesterase
622 Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease
623 Dementia", Alzheimer Disease & Associated Disorders, vol. 33, no. 2, pp. 87-94.

624 Hill, K.S., Bishop, J.R., Palumbo, D. & Sweeney, J.A. 2010, "Effect of second-generation
625 antipsychotics on cognition: current issues and future challenges", Expert Review of
626 Neurotherapeutics, vol. 10, no. 1, pp. 43-57.

627 Hsu, C., Wahlqvist, M.L., Lee, M. & Tsai, H. 2011, "Incidence of dementia is increased in type
628 2 diabetes and reduced by the use of sulfonylureas and metformin.", Journal of Alzheimer's
629 Disease, vol. 24, no. 3, pp. 485-493.

630 Ikeda M., Kataoka H. & Ueno, S. 2017, "Can levodopa prevent cognitive decline in patients
631 with Parkinson's disease?.", American Journal of Neurodegenerative Diseases, vol. 6, no. 2,
632 pp. 9-14.

633 Imbimbo, B. P., Solfrizzi, V., & Panza, F. 2010, “Are NSAIDs useful to treat Alzheimer's disease
634 or mild cognitive impairment?.” Frontiers in aging neuroscience, vol. 2, pp. 19.

635 Jamsen, K.M.P.D., Ilomaki, J.P.D., Hilmer, S.N.P.D., Jokanovic, N.B.P., Tan, E.C.K.P.D. & Bell,
636 S.J.P.D. 2016, "A systematic review of the statistical methods in prospective cohort studies
637 investigating the effect of medications on cognition in older people", Research In Social &
638 Administrative Pharmacy, vol. 12, no. 1, pp. 20-28.

639 Joshi, A., Wang, D. H., Watterson, S., McClean, P. L., Behera, C. K., Sharp, T., & Wong-Lin, K.
640 (2020). Opportunities for multiscale computational modelling of serotonergic drug effects in
641 Alzheimer's disease. Neuropharmacology, 174, 108118.

642 Kaur, D., Bucholc, M., Finn, D.P., Todd, S., Wong-Lin, K. & McClean, P.L. 2020, "Multi-time-
643 point data preparation robustly reveals MCI and dementia risk factors.", Alzheimer's &
644 Dementia : Diagnosis, Assessment & Disease Monitoring, vol. 12, no. 1, pp. e12116.

645 Kim, J.Y., Ku, Y.S., Kim, H.J., Trinh, N.T., Kim, W., Jeong, B., Heo, T.Y., Lee, M.K. & Lee, K.E.
646 2019, "Oral diabetes medication and risk of dementia in elderly patients with type 2
647 diabetes.", Diabetes Research & Clinical Practice, vol. 154, pp. 116-123.

648 Kotilinek, L. A., Westerman, M. A., Wang, Q., Panizzon, K., Lim, G. P., Simonyi, A., Lesne, S.,
649 Falinska, A., Younkin, L. H., Younkin, S. G., Rowan, M., Cleary, J., Wallis, R. A., Sun, G. Y., Cole,
650 G., Frautschy, S., Anwyl, R., & Ashe, K. H. 2008. Cyclooxygenase-2 inhibition improves amyloid-
651 beta-mediated suppression of memory and synaptic plasticity. Brain : a journal of neurology,
652 131(Pt 3), 651–664.

653 Kukull, W.A. (2015) NACC UNIFORM DATA SET. Researchers Data Dictionary. Available at:
654 https://files.alz.washington.edu/documentation/uds3-rdd.pdf (Accessed: 05.03.2022).

655 Lee, Z. X., Ang, E., Lim, X. T., & Arain, S. J. 2021. Association of Risk of Dementia With Direct
656 Oral Anticoagulants Versus Warfarin Use in Patients With Non-valvular Atrial Fibrillation: A
657 Systematic Review and Meta-analysis. Journal of cardiovascular pharmacology, 77(1), 22–31.

658 Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns,
659 A., Cohen-Mansfield, J., Cooper, C., Costafreda, S.G., Dias, A., Fox, N., Gitlin, L.N., Howard, R.,
660 Kales, H.C., Kivimaki, M., Larson, E.B., Ogunniyi, A., Orgeta, V., Ritchie, K., Rockwood, K.,
661 Sampson, E.L., Samus, Q., Schneider, L.S., Selbaek, G., Teri, L. & Mukadam, N. 2020, "Dementia
662 prevention, intervention, and care: 2020 report of the Lancet Commission", Lancet, vol. 396,
663 no. 10248, pp. 413-446.

McCombe, N., Liu, S., Ding, X., Prasad, G., Bucholc, M., Finn, D. P., Todd, S., McClean, P. L., & Wong-Lin, K. (2022). Practical Strategies for Extreme Missing Data Imputation in Dementia Diagnosis. IEEE journal of biomedical and health informatics, 26(2), 818–827. https://doi.org/10.1109/JBHI.2021.3098511

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. & Stadlan, E.M. 1984, "Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.", Neurology, vol. 34, no. 7, pp. 939-944.

McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R.J., Kawas, C.H., Klunk, W.E., Koroshetz, W.J., Manly, J.J., Mayeux, R., Mohs, R.C., Morris, J.C., Rossor, M.N., Scheltens, P., Carrillo, M.C., Thies, B., Weintraub, S. & Phelps, C.H. 2011, "The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.", Alzheimer's & Dementia, vol. 7, no. 3, pp. 263-269.

Moore, E.M., Mander, A.G., Ames, D., Kotowicz, M.A., Carne, R.P., Brodaty, H., Woodward, M., Boundy, K., Ellis, K.A., Bush, A.I., Faux, N.G., Martins, R., Szoeke, C., Rowe, C., Watters, D.A. & AIBL Investigators 2013, "Increased risk of cognitive impairment in patients with diabetes is associated with metformin.", Diabetes care, vol. 36, no. 10, pp. 2981-2987.

Morris, J.C. 1993, "The Clinical Dementia Rating (CDR): Current version and scoring rules", Neurology, vol. 43, no. 11, pp. 2412-2414.

Morris, J.C., Weintraub, S., Chui, H.C., Cummings, J., Decarli, C., Ferris, S., Foster, N.L., Galasko, D., Graff-Radford, N., Peskind, E.R., Beekly, D., Ramos, E.M. & Kukull, W.A. 2006, "The Uniform

686 Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease
687 Centers.", Alzheimer Disease & Associated Disorders, vol. 20, no. 4, pp. 210-216.

688 Newcombe, E.A., Camats-Perna, J., Silva, M.L., Valmas, N., Huat, T.J. & Medeiros, R. 2018,
689 "Inflammation: the link between comorbidities, genetics, and Alzheimer's disease", Journal of
690 Neuroinflammation, vol. 15, no. 1, pp. 276.

691 Nikaido A.M., Ellinwood Jr. E.H., Heatherly D.G. & Gupta, S.K. 1990, "Age-related increase in
692 CNS sensitivity to benzodiazepines as assessed by task difficulty.", Psychopharmacology, vol.
693 100, no. 1, pp. 90-97.

694 Nishtala P.S., Salahudeen M.S. & Hilmer, S.N. 2016, "Anticholinergics: theoretical and clinical
695 overview.", Expert Opinion on Drug Safety, vol. 15, no. 6, pp. 753-768.

696 Obermann K.R., Morris J.C. & Roe, C.M. 2013, "Exploration of 100 commonly used drugs and
697 supplements on cognition in older adults.", Alzheimer's and Dementia, vol. 9, no. 6, pp. 724-
698 732.

699 O'Bryant S.E., Lacritz L.H., Hall J., Waring S.C., Chan W., Khodr Z.G., Massman P.J., Hobson V.
700 & Cullum, C.M. 2010, "Validation of the new interpretive guidelines for the clinical dementia
701 rating scale sum of boxes score in the National Alzheimer's Coordinating Center database.",
702 Archives of Neurology, vol. 67, no. 6, pp. 746-749.

703 Ou, Y., Tan, C., Shen, X., Xu, W., Hou, X., Dong, Q., Tan, L. & Yu, J. 2020, "Blood Pressure and
704 Risks of Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis of 209
705 Prospective Studies", Hypertension, vol. 76, no. 1, pp. 217-225.

706 Peters, R., Booth, A., Rockwood, K., Peters, J., D'Este, C. & Anstey, K.J. 2019, "Combining
707 modifiable risk factors and risk of dementia: a systematic review and meta-analysis.", BMJ
708 Open, vol. 9, no. 1, pp. e022846.

709 Petersen R.C. & Morris, J.C. 2005, "Mild cognitive impairment as a clinical entity and
710 treatment target.", Archives of Neurology, vol. 62, no. 7, pp. 1160-1163.

711 Raj, D., Yin, Z., Breur, M., Doorduin, J., Holtman, I.R., Olah, M., Mantingh-Otter, I.J., Van Dam,
712 D., De Deyn, P.P., den Dunnen, W., Eggen, B.J.L., Amor, S. & Boddeke, E. 2017, "Increased
713 White Matter Inflammation in Aging- and Alzheimer's Disease Brain.", Frontiers in Molecular
714 Neuroscience, vol. 10, pp. 206.

715 Rouch, L., Cestac, P., Hanon, O., Cool, C., Helmer, C., Bouhanick, B., Chamontin, B., Dartigues,
716 J., Vellas, B. & Andrieu, S. 2015, "Antihypertensive drugs, prevention of cognitive decline and
717 dementia: a systematic review of observational studies, randomized controlled trials and
718 meta-analyses, with discussion of potential mechanisms.", CNS Drugs, vol. 29, no. 2, pp. 113-
719 130.

720 Salahudeen M.S., Duffull S.B. & Nishtala, P.S. 2015, "Anticholinergic burden quantified by
721 anticholinergic risk scales and adverse outcomes in older people: a systematic review.", BMC
722 geriatrics, vol. 15, pp. 31.

723 Salzman, C. 2020, "Do Benzodiazepines Cause Alzheimer's Disease?.", American Journal of
724 Psychiatry, vol. 177, no. 6, pp. 476-478.

725 Schneider, L.S., Insel, P.S., Weiner, M.W. & for the Alzheimer's Disease Neuroimaging
726 Initiative 2011, "Treatment With Cholinesterase Inhibitors and Memantine of Patients in the
727 Alzheimer's Disease Neuroimaging Initiative", Archives of Neurology, vol. 68, no. 1, pp. 58-66.

728 Schultz, B. G., Patten, D. K., & Berlau, D. J. 2018. The role of statins in both cognitive
729 impairment and protection against dementia: a tale of two mechanisms. Translational
730 neurodegeneration, 7, 5.

731 Seaquist, E. R., Miller, M. E., Fonseca, V., Ismail-Beigi, F., Launer, L. J., Punthakee, Z., & Sood,
732 A. 2013. Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND.
733 Journal of diabetes and its complications, 27(5), 485–491.

734 Shah, K., Qureshi, S.U., Johnson, M., Parikh, N., Schulz, P.E. & Kunik, M.E. 2009, "Does use of
735 antihypertensive drugs affect the incidence or progression of dementia? A systematic
736 review.", American Journal of Geriatric Pharmacotherapy, vol. 7, no. 5, pp. 250-261.

737 Trenaman, S.C., Rideout, M. & Andrew, M.K. 2019, "Sex and gender differences in
738 polypharmacy in persons with dementia: A scoping review.", SAGE Open Medicine, vol. 7, pp.
739 2050312119845715.

740 Verdoux, H., Lagnaoui, R. & Begaud, B. 2005, "Is benzodiazepine use a risk factor for cognitive
741 decline and dementia? A literature review of epidemiological studies.", Psychological
742 medicine, vol. 35, no. 3, pp. 307-315.

743 Wancata, J., Borjesson-Hanson, A., Ostling, S., Sjogren, K. & Skoog, I. 2007, "Diagnostic criteria
744 influence dementia prevalence.", American Journal of Geriatric Psychiatry, vol. 15, no. 12, pp.
745 1034-1045.

746 Woodling, N. S., Colas, D., Wang, Q., Minhas, P., Panchal, M., Liang, X., Mhatre, S. D., Brown,
747 H., Ko, N., Zagol-Ikapitte, I., van der Hart, M., Khroyan, T. V., Chuluun, B., Priyam, P. G., Milne,
748 G. L., Rassoulpour, A., Boutaud, O., Manning-Boğ, A. B., Heller, H. C., & Andreasson, K. I. 2016.
749 Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's

750 disease model mice. Brain : a journal of neurology, 139(Pt 7), 2063–2081.
751 https://doi.org/10.1093/brain/aww117

752 Wu C.Y., Ouk M., Wong Y.Y., Anita N.Z., Edwards J.D., Yang P., Shah B.R., Herrmann N., Lanctot
753 K.L., Kapral M.K., MacIntosh B.J., Rabin J.S., Black S.E. & Swardfager, W. 2020, "Relationships
754 between memory decline and the use of metformin or DPP4 inhibitors in people with type 2
755 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status.",
756 Alzheimer's and Dementia, vol. 16, no. 12, pp. 1663-1673.

757 Xiong, G., Yang, Z., Yi, J., Wang, N., Wang, L., Zhu, H., Wu, C., Lu, A., Chen, X., Liu, S., Hou, T.,
758 & Cao, D. 2022. DDInter: an online drug-drug interaction database towards improving clinical
759 decision-making and patient safety. Nucleic acids research, 50(D1), D1200–D1207.

760 Zammitt, N.N.M. & Frier, B.M. 2005, "Hypoglycemia in Type 2 Diabetes: Pathophysiology,
761 frequency, and effects of different treatment modalities", Diabetes care, vol. 28, no. 12, pp.
762 2948-2961.

763 Zeng, D., Jiang, C., Su, C., Tan, Y., & Wu, J. (2019). Anticoagulation in atrial fibrillation and
764 cognitive decline: A systematic review and meta-analysis. Medicine, 98(7), e14499.

765 Zhang, C., Wang, Y., Wang, D., Zhang, J. & Zhang, F. 2018, "NSAID Exposure and Risk of
766 Alzheimer's Disease: An Updated Meta-Analysis From Cohort Studies.", Frontiers in aging
767 neuroscience, vol. 10, pp. 83.




Fig. 1: Data preparation process for progression groups within the NACC dataset. (AD: Alzheimer's Disease; CDRSOB: Clinical Dementia Rating Sum of Boxes; MCI: Mild Cognitive Impairment; NACC: National Alzheimer's Coordinating Center).




Fig. 2: Summary grouped forest plots of adjusted odds ratios for drug classes significantly associated with risk of progression to dementia and AD for two diagnostic variables; clinical diagnosis and CDRSOB scores. (AD: Alzheimer's Disease; MCI: Mild Cognitive Impairment; CDRSOB: Clinical Dementia Rating sum of boxes; CI: Confidence Intervals). *$p<0.05$, **$p<0.01$, ***$p<0.001$, ****$p<0.0001$.




Fig. 3: Summary grouped forest plots of adjusted odds ratios for drug subcategories significantly associated with reduced risk of progression to MCI, dementia, and AD for two diagnostic variables; clinical diagnosis and CDRSOB scores. Drug classes analysed: (A) Anticoagulants and Parkinson's medication; (B) Antihypertensives and NSAIDs; (C) Antidepressants. (AD: Alzheimer's Disease; CDRSOB: Clinical Dementia Rating sum of boxes; CI: Confidence Intervals; COX: Cyclooxygenase-2; MCI: Mild Cognitive Impairment; NDRIs: Norepinephrine-dopamine reuptake inhibitors; SARIs: Serotonin antagonist and reuptake inhibitors). *$p<0.05$, **$p<0.01$, ***$p<0.001$, ****$p<0.0001$.




Fig. 4: Summary grouped forest plots of adjusted odds ratios for drug subcategories significantly associated with increased risk of progression to dementia and AD for two diagnostic variables; clinical diagnosis and CDRSOB scores. Drug classes analysed: Hypolipidemic agents and Diabetes medication. (AD: Alzheimer's Disease; CDRSOB: Clinical Dementia Rating sum of boxes; CI: Confidence Intervals; MCI: Mild Cognitive Impairment). *$p<0.05$.




Fig. 5: Summary grouped forest plots of adjusted odds ratios for AD drugs significantly associated with risk of progression to dementia and AD for two diagnostic variables; clinical diagnosis and CDRSOB scores. Progression groups analysed: (A) Remained MCI vs. MCI-to-Dementia; (B) Remained MCI vs. MCI-to-AD. (AD: Alzheimer's Disease; CDRSOB: Clinical Dementia Rating sum of boxes; CI: Confidence Intervals; MCI: Mild Cognitive Impairment). *$p<0.05$, **$p<0.01$, ***$p<0.001$, ****$p<0.0001$.